- Home
- HTLD vs TYRA Comparison
HTLD vs TYRA Comparison
Compare HTLD & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTLD
- TYRA
- Stock Information
- Founded
- HTLD 1978
- TYRA 2018
- Country
- HTLD United States
- TYRA United States
- Employees
- HTLD N/A
- TYRA N/A
- Industry
- HTLD Trucking Freight/Courier Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- HTLD Industrials
- TYRA Health Care
- Exchange
- HTLD Nasdaq
- TYRA Nasdaq
- Market Cap
- HTLD 622.9M
- TYRA 571.9M
- IPO Year
- HTLD N/A
- TYRA 2021
- Fundamental
- Price
- HTLD $8.76
- TYRA $11.71
- Analyst Decision
- HTLD Hold
- TYRA Strong Buy
- Analyst Count
- HTLD 5
- TYRA 7
- Target Price
- HTLD $9.70
- TYRA $30.43
- AVG Volume (30 Days)
- HTLD 729.9K
- TYRA 201.1K
- Earning Date
- HTLD 07-24-2025
- TYRA 08-14-2025
- Dividend Yield
- HTLD 0.97%
- TYRA N/A
- EPS Growth
- HTLD N/A
- TYRA N/A
- EPS
- HTLD N/A
- TYRA N/A
- Revenue
- HTLD $932,244,000.00
- TYRA N/A
- Revenue This Year
- HTLD N/A
- TYRA N/A
- Revenue Next Year
- HTLD $5.81
- TYRA N/A
- P/E Ratio
- HTLD N/A
- TYRA N/A
- Revenue Growth
- HTLD N/A
- TYRA N/A
- 52 Week Low
- HTLD $7.11
- TYRA $6.42
- 52 Week High
- HTLD $12.85
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- HTLD 58.42
- TYRA 61.31
- Support Level
- HTLD $8.00
- TYRA $9.96
- Resistance Level
- HTLD $8.62
- TYRA $11.48
- Average True Range (ATR)
- HTLD 0.34
- TYRA 0.73
- MACD
- HTLD 0.09
- TYRA 0.06
- Stochastic Oscillator
- HTLD 96.58
- TYRA 75.43
About HTLD Heartland Express Inc.
Heartland Express Inc is engaged in providing truckload services across the United States, Mexico, and Canada. These truckload services are asset-based transportation services in the dry van truckload market. The company offers truckload temperature-controlled transportation services, and Mexico logistics services. A majority of its customers represent the consumer goods, appliances, food products, and automotive industries.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.